NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of Melissa Epperly as Chief Financial Officer (CFO).
Ms. Epperly joins Zentalis with deep corporate finance and healthcare operational experience, including both commercial and clinical-stage CFO roles, as well as investing, investment banking and consulting experience in life sciences. Ms. Epperly will lead all finance-related and investor relations functions and report directly to Zentalis Chairman and Chief Executive Officer, Dr. Anthony Sun.
“Melissa is a proven finance leader with extensive experience working in private and public company settings, and she will be a tremendous asset to Zentalis and our leadership team,” said Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals. “As we develop our clinical pipeline and focus Zentalis for the future, Melissa’s strategic mindset and broad leadership experience will prove invaluable.”
Ms. Epperly brings expertise as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy cancer company, and prior to that, CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology pharmaceutical company. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company focused on international and US-based pharmaceutical clients and private equity. She began her career at Morgan Stanley in New York in healthcare investment banking. Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia.
“I am excited to be joining Zentalis at such a dynamic time as the Company advances its targeted small molecule pipeline in oncology at a rapid pace of development. The Company is at the forefront of optimizing small molecule therapies for cancer, and I look forward to working with Zentalis’ senior leadership team and its employees to help bring new innovative therapies to patients with cancer,” said Melissa Epperly, MBA, Chief Financial Officer at Zentalis Pharmaceuticals.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. In addition to its lead program, ZN-c5, an oral SERD for estrogen receptor positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need. The Company has offices in New York and San Diego. For more information, please visit www.zentalis.com.
